These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial
results; Gilead's ability to sustain growth
in revenues for its antiviral and
other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures
in European
countries that may increase the amount of discount required on Gilead's products; an increase
in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger
than anticipated shift
in payer mix to more highly discounted payer segments and geographic regions and decreases
in treatment duration; availability of funding for
state AIDS Drug Assistance Programs (ADAPs); continued fluctuations
in ADAP purchases driven by federal and
state grant cycles which may not mirror patient demand and may cause fluctuations
in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or
other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable
results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials
in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations
in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates
in the timelines currently anticipated; Gilead's ability to receive regulatory approvals
in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over
other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta
in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes
in its stock price, corporate or
other market conditions; fluctuations
in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and
other risks identified from time to time
in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).
In the United States, new teachers only make an average of about $ 36,000, and the average salary for all teachers is just over $ 58,000 — which, in today's dollars, is lower than the average salary during the 1989 - 1990 school year.63 Teachers make 60 percent of what similarly educated professionals earn, much lower than the proportion in other Organisation for Economic Cooperation and Development (OECD) countries.64 Partly as a result of low teacher pay, young people are avoiding the teaching profession, excellent teachers are staying away from high - need schools, the teaching profession is not as diverse as it needs to be, and far too many great educators leave the profession altogether.
In the United
States, new teachers only make an average of about $ 36,000, and the average salary for all teachers is just over $ 58,000 — which,
in today's dollars, is lower than the average salary during the 1989 - 1990 school year.63 Teachers make 60 percent of what similarly educated professionals earn, much lower than the proportion in other Organisation for Economic Cooperation and Development (OECD) countries.64 Partly as a result of low teacher pay, young people are avoiding the teaching profession, excellent teachers are staying away from high - need schools, the teaching profession is not as diverse as it needs to be, and far too many great educators leave the profession altogether.
in today's dollars, is lower
than the average salary during the 1989 - 1990 school year.63 Teachers make 60 percent of what similarly educated professionals earn, much lower
than the proportion
in other Organisation for Economic Cooperation and Development (OECD) countries.64 Partly as a result of low teacher pay, young people are avoiding the teaching profession, excellent teachers are staying away from high - need schools, the teaching profession is not as diverse as it needs to be, and far too many great educators leave the profession altogether.
in other Organisation for Economic Cooperation and Development (OECD)
countries.64 Partly as a
result of low teacher pay, young people are avoiding the teaching profession, excellent teachers are staying away from high - need schools, the teaching profession is not as diverse as it needs to be, and far too many great educators leave the profession altogether.65